Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

GemOx

3 posts
RRoche
Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
Read More

Health Canada Approves Roche’s Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy

  • 2026-03-06
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study

  • 2026-02-22
F. Hoffmann-La Roche Ltd Overall survival was twice as long for people treated with Columvi in combination with…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s Columvi combo doubles survival in three-year DLBCL study

  • 2026-02-13
Roche (RHHBY) reported three-year follow-up from the phase III STARGLO study in relapsed/refractory…
Switzerland
www.europesays.com